Retroperitoneal liposarcoma is a rare solid tumour of mesenchymal origin with an incidence of 2.5 per million population. We report what is, to the best of our knowledge, the first case in the English literature of retroperitoneal liposarcoma in an adult patient with Down syndrome. The tumour was surgically resected with no use of adjuvant chemotherapy or radiation. No recurrence was found at follow-up 2 months postoperatively. Clinicians should consider retroperitoneal liposarcoma in the differential diagnosis of abdominal distention in adult patients with Down syndrome.
Download full-text PDF |
Source |
---|
Ann Surg Oncol
January 2025
Department of Surgery, Clarunis St. Clara Hospital & University Hospital Basel, Basel, Switzerland.
Cureus
December 2024
General Surgery, Dr. D Y Patil Medical College, Hospital and Research Centre, Dr. D Y Patil Vidyapeeth (Deemed to be University), Pune, IND.
Retroperitoneal liposarcoma is a rare malignancy that arises from adipocytes and can expand significantly before manifesting clinical symptoms. Instances of giant retroperitoneal liposarcoma, defined as tumors larger than 30 cm, are extremely rare, with fewer than 20 reported cases. This case report presents a 68-year-old patient with a significant abdominal mass, ultimately identified and treated as a well-differentiated retroperitoneal liposarcoma.
View Article and Find Full Text PDFInt J Mol Sci
December 2024
The James Comprehensive Cancer Center, Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Retroperitoneal liposarcoma (RPLPS) is one of the most common histologic subtypes of soft tissue sarcoma (STS). Complete surgical resection remains the mainstay treatment, while the high rate of locoregional recurrence constitutes the predominant cause of mortality. Well-differentiated (WDLPS) and dedifferentiated (DDLPS) liposarcoma are the most frequent subtypes of RPLPS and present amplified MDM2 gene as a hallmark.
View Article and Find Full Text PDFBackground: Management of retroperitoneal liposarcoma (RPLPS) is challenging and recurrence rates remain high despite aggressive surgical resections. Preoperative radiation alone lacks definitive benefit, thus we sought to evaluate combined chemoradiotherapy with the potential to enhance local efficacy of radiation as well as control micrometastatic disease. We assessed the safety and tolerability of preoperative eribulin, a cytotoxic microtubule inhibitor approved for the treatment of advanced liposarcoma, in combination with radiation in patients with RPLPS.
View Article and Find Full Text PDFAnn Surg Oncol
January 2025
Department of Surgery, Clarunis - St. Clara Hospital & University Hospital Basel, Basel, Switzerland.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!